'Vaccine price to be outcome of scale; have output capacity of 30 mn doses per month'

‘Vaccine price to be outcome of scale; have output capacity of 30 mn doses per month’
In an interview to PRABHA RAGHAVAN, Singh details how the Pune firm’s vaccine works and delves into plans to test and scale up production for a vast population. Edited excerpts:
Updated: December 26, 2020 4:05:35 pm
Dr Sanjay Singh.
The mRNA Covid-19 vaccine by Gennova Biopharmaceuticals will hopefully not only achieve a similar efficacy to the candidates developed by Pfizer and Moderna, but will also be more affordably priced for a country like India, according to CEO Dr Sanjay Singh.
How does your mRNA vaccine, which uses a self-amplifying model, compare with Pfizer and Moderna’s candidates?

Related Keywords

South Africa ,India ,Kolhapur ,Maharashtra ,Brazil ,Pune ,Sanjay Singh ,Pfizer ,Central Drugs Standard Control Organisation ,Gennova Biopharmaceuticals ,Drug Controller General ,Covid 19 In India ,Covid 19 Vaccine In India ,Gennova Biopharmaceuticals Covid Vaccine ,Indian Express News ,இந்தியா ,கோலாப்பூர் ,மகாராஷ்டிரா ,பிரேசில் ,புனே ,சஞ்சய் சிங் ,ஃபைசர் ,மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் ,மருந்து கட்டுப்படுத்தி ஜநரல் ,இந்தியன் எக்ஸ்பிரஸ் செய்தி ,